Raymond James Financial
NKTR icon

Raymond James Financial’s Nektar Therapeutics NKTR Stock Holding History

Raymond James Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$653K Buy
9,357
+6,404
+217% +$469K ﹤0.01% 4318
2026
Q1 		$212K Buy
+2,953
New +$168K ﹤0.01% 4857
2025
Q3 		– Sell
-313
Closed -$8.09K – 6108
2025
Q2 		$8.09K Buy
+313
New +$3.51K ﹤0.01% 6007

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's NKTR Position: Q2 2026 in Review

Raymond James Financial increased its Nektar Therapeutics (NKTR) stake by 217% in Q2 2026, buying an estimated $469K and bringing the position to 9,357 shares worth $653K. The position accounts for ﹤0.01% of the portfolio, ranked #4318.

Raymond James Financial first reported a position in NKTR in Q2 2025 and has held it in 3 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Raymond James Financial held 9,357 shares of Nektar Therapeutics worth $653K as of Q2 2026.
  • Raymond James Financial bought 6,404 Nektar Therapeutics shares in Q2 2026, an estimated $469K.
  • Nektar Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4318 holding.
  • Raymond James Financial first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.